MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia.

Trial Profile

MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms MABTENANCE
  • Most Recent Events

    • 23 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
    • 23 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top